Skip to content

Michael Farrell

9 papers in the library · 22 citations · publishing 2003-2026

Papers

Sort Most recent Most cited

Cannabis and cannabinoids for the treatment of mental and substance use disorders and symptoms: A systematic review and meta-analysis of experimental and observational studies.

Psychiatry Research August 1, 2026 C. Bharat, Xin-Tong Huang, G. Campbell et al.

BACKGROUND Interest in cannabinoids for mental and substance use disorders is increasing. We examined experimental and observational evidence for treating these disorders and their symptoms. METHODS Systematic review and meta-analysis (PROSPERO CRD42023467536). We searched CENTRAL, MEDLINE, Embase and PsycINFO to May 2025 for studies of cannabinoids in adults (≥18 years) with ADHD, anxiety,...

The toxicology and characteristics of fatal new psychoactive stimulant and hallucinogen-related poisonings in Australia, 2000–2025

Drug and Alcohol Dependence Reports March 22, 2026 Shane Darke, Johan Duflou, Michael Farrell et al.

New psychoactive stimulants and hallucinogens (NPSH) poisonings have generated considerable public health concern in recent years. We aimed to determine: 1. The characteristics, toxicology and major autopsy findings of known cases of NBZD-related poisoning in Australia, 2000-2025; and 2. Changes in characteristics of known cases from 2020 onwards compared to earlier known cases. Retrospective...

DOI: 10.1016/j.dadr.2026.100434 (opens in new tab) Stimulant Poison control Psychoactive drug Toxicology +2

A retrospective study of the characteristics and toxicology of cases of lysergic acid diethylamide (LSD)‐ and psilocybin‐related death in Australia

Addiction May 21, 2024 Shane Darke, Johan Duflou, Amy Peacock et al. 14 citations

Abstract Background and aims Lysergic acid diethylamide (LSD) and psilocybin are used as recreational drugs, and there is renewed interest in their clinical use. The current study aimed to (1) determine the circumstances of death and case characteristics of LSD‐ and psilocybin‐related death in Australia, 2000–23; and (2) determine the toxicological profile and major autopsy findings of these...

Psychotogenic potential of prescribed drugs

Australian & New Zealand Journal of Psychiatry May 6, 2023 Julia Lappin, Shane Darke, Michael Farrell

Australian & New Zealand Journal of Psychiatry, 57(6) Interest in prescribing psychoactive drugs as treatments for mental health conditions has been highlighted recently by the decision by the Therapeutic Goods Administration (TGA) to permit, from 1 July 2023, authorised psychiatrists to prescribe medicines containing psilocybin for treatment-resistant depression and...

'Synthetic cannabis': A dangerous misnomer.

International Journal of Drug Policy December 1, 2021 Shane Darke, Samuel D Banister, Michael Farrell et al.

The term 'synthetic cannabis' has been widely used in public discourse to refer to a group of cannabinoid receptor agonists. In this paper we detail the characteristics of these drugs, and present the case that the term is a misnomer. We describe the pharmacodynamics of these drugs, their epidemiology, mechanisms of action, physiological effects and how these differ substantially from...

DOI: 10.1016/j.drugpo.2021.103396 (opens in new tab) Full text (opens in new tab) Cannabinoids Morbidity Synthetic cannabis Toxicity +1

Aldous Huxley's Doors of Perception.

Addiction October 11, 2021 Wayne Hall, Michael Farrell

Aldous Huxley's personal account of his experience taking mescaline in The Doors of Perception (1954) has influenced popular understandings of the effects of psychedelic drugs and encouraged many personal experiences with these drugs. Huxley encouraged the psychiatrist Humphry Osmond to coin the term 'psychedelic'. He knew many of the leading figures in early psychedelic research and advocated...

What can we learn from the history of research on psychedelic drugs in the addictions?

Addiction August 12, 2021 Wayne Hall, Michael Farrell 8 citations

The history of research on the use of psychedelic drugs to treat alcohol dependence in the 1950s and 1960s suggests the need for caution in their proposed clinical use. Since 2006 there has been a revival of interest in using psychedelics to treat depression and post-traumatic stress disorders [1] and the addictions [2]. What lessons may we glean from research in the 1950s and 1960s on the use...

Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: A systematic review and meta-analysis

The Lancet Psychiatry October 28, 2019 N. Black, E. Stockings, G. Campbell et al.

Background: Medicinal cannabinoids, including medicinal cannabis, pharmaceutical cannabinoids and their synthetic derivatives, including tetrahydrocannabinol (THC) and or cannabidiol (CBD), have been suggested to have a therapeutic role for certain mental health conditions. The primary objective was to review the evidence for cannabinoids in treating symptoms of depression, anxiety,...

Neural correlates of the emergence of consciousness of thirst.

Proceedings of the National Academy of Sciences December 9, 2003 Gary F. Egan, Tim Silk, Frank Zamarripa et al.

Thirst was induced by rapid i.v. infusion of hypertonic saline (0.51 M at 13.4 ml/min). Ten humans were neuroimaged by positron-emission tomography (PET) and four by functional MRI (fMRI). PET images were made 25 min after beginning infusion, when the sensation of thirst began to enter the stream of consciousness. The fMRI images were made when the maximum rate of increase of thirst occurred....